SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Aptevo Reports Fewer Mipletamig Infusion Reactions

Aptevo said successive refinements to mipletamig’s priming-dose regimen substantially reduced infusion-related reactions during initial treatment. The RAINIER study is expected to be completed by year-end 2026, with Phase 2 development planned for 2027.

APVO

Related stories